Jean Jacques Bienaime Sells 20,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) Director Jean Jacques Bienaime sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $81.62, for a total transaction of $1,632,400.00. Following the completion of the sale, the director now owns 474,994 shares in the company, valued at approximately $38,769,010.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

• On Friday, April 12th, Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $91.26, for a total value of $1,825,200.00.
• On Tuesday, March 5th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $85.51, for a total transaction of $85,510.00.
• On Tuesday, February 27th, Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.35, for a total transaction of $90,350.00.

BioMarin Pharmaceutical Price Performance

BMRN traded down $0.53 during midday trading on Monday, hitting $80.50. 1,291,756 shares of the company traded hands, compared to its average volume of 1,446,103. The company has a market capitalization of $15.29 billion, a price-to-earnings ratio of 75.23, a PEG ratio of 1.28 and a beta of 0.34. The business has a 50 day simple moving average of $86.22 and a two-hundred day simple moving average of $89.00. The company has a current ratio of 2.74, a quick ratio of 1.70 and a debt-to-equity ratio of 0.12. BioMarin Pharmaceutical Inc. has a 52-week low of $76.02 and a 52-week high of $99.56.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $646.21 million during the quarter, compared to the consensus estimate of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. The firm's revenue was up 20.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.11 EPS. On average, equities analysts forecast that BioMarin Pharmaceutical Inc. will post 1.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of hedge funds have recently modified their holdings of the company. KB Financial Partners LLC boosted its position in shares of BioMarin Pharmaceutical by 51.3% during the 3rd quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 118 shares during the period. Lindbrook Capital LLC boosted its position in shares of BioMarin Pharmaceutical by 259.8% during the fourth quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company's stock worth $37,000 after buying an additional 278 shares during the period. Benjamin F. Edwards & Company Inc. grew its stake in shares of BioMarin Pharmaceutical by 135.3% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the biotechnology company's stock valued at $42,000 after buying an additional 249 shares in the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at $43,000. Finally, First Horizon Advisors Inc. lifted its stake in BioMarin Pharmaceutical by 33.3% during the 4th quarter. First Horizon Advisors Inc. now owns 576 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 144 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

Analyst Ratings Changes

BMRN has been the subject of a number of analyst reports. Citigroup cut their price target on BioMarin Pharmaceutical from $94.00 to $91.00 and set a "neutral" rating for the company in a research note on Thursday, April 25th. Royal Bank of Canada reissued a "sector perform" rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Piper Sandler cut their price objective on shares of BioMarin Pharmaceutical from $115.00 to $107.00 and set an "overweight" rating for the company in a report on Friday, February 23rd. Scotiabank boosted their target price on shares of BioMarin Pharmaceutical from $83.00 to $85.00 and gave the stock a "sector perform" rating in a report on Thursday, April 25th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $110.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, April 25th. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $107.50.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.